In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells

In order to understand further the effects of Newcastle-disease-virus(NDV)-modified tumour vaccines we investigated the feasibility of isolating lymphocytes from the site of injection of patients undergoing postoperative active specific immunization (ASI) with autologous NDV-modified tumour cells. D...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Immunology Immunotherapy 1993-09, Vol.37 (4), p.240-244
Hauptverfasser: STOECK, M, MARLAND-NOSKE, C, MANASTERSKI, M, ZAWATZKY, R, HORN, S, MÖBUS, V, SCHLAG, P, SCHIRRMACHER, V
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 244
container_issue 4
container_start_page 240
container_title Cancer Immunology Immunotherapy
container_volume 37
creator STOECK, M
MARLAND-NOSKE, C
MANASTERSKI, M
ZAWATZKY, R
HORN, S
MÖBUS, V
SCHLAG, P
SCHIRRMACHER, V
description In order to understand further the effects of Newcastle-disease-virus(NDV)-modified tumour vaccines we investigated the feasibility of isolating lymphocytes from the site of injection of patients undergoing postoperative active specific immunization (ASI) with autologous NDV-modified tumour cells. Delayed-type-hypersensitivity(DTH)-like reactions from five cancer patients were surgically removed, minced and the tissue particles were digested with collagenase and DNase. Lymphoid cells recovered were expanded in a highly efficient limiting-dilution analysis system optimized for T cell growth [Moretta et al. (1983) J Exp Med 157: 743] and lymphocyte microcultures (clonal probability > 0.8) could be grown for up to 1 year. Analysis of the microcultures for phenotype and function showed that the majority were positive for CD4 (92%) and TCR alpha beta (96%). Concanavalin-A-induced production of interleukin-2 (IL-2), IL-6, interferon gamma and tumour necrosis factor alpha was detected in more than 70% of the microcultures. Lectin-dependent cytotoxicity was only very rarely observed. The general characteristics of the microcultures obtained support the notion of a DTH-like reaction taking place at the site of tumour cell challenge. The possibility of in vitro expansion and cultivation of T lymphocytes from ASI vaccination sites should help to elucidate further the role of these cells in active specific immunization against autologous tumour cells.
doi_str_mv 10.1007/BF01518517
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11038618</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75882294</sourcerecordid><originalsourceid>FETCH-LOGICAL-c367t-5e4148b912545467fe8b6e130b3c619a9d9d7820bb0457759695462b2c6163063</originalsourceid><addsrcrecordid>eNpVUk1v1DAUjBCobAsX7kg-IA6VAnbsJM4JlYpCpQou5Rw5zsvuQ44d_LFl-an8GrzsaoGD5Y-ZN36jeUXxgtE3jNL27fsbymoma9Y-KlZM8Kqk-fK4WFEuaNlSKp4W5yF8y4eKdt1ZcSa5kHXDV8WvW0u2GL0j8GNRNqCzRNkxL2V2AQNxE7knZjcvG6d3EciM2judTEweMjpEhRZGMnk3k7gBslVao1VxLxQwwh8FrawGT5b8DDYGkuwIfu3QronSEbdAwgIaJ9QE5zlZ_HkQeMC4ISpFZ9zapUA-w4NWIRooRwygApRb9CmUsxtzcW4jptklTzQYE54VTyZlAjw_7hfF15sP99efyrsvH2-vr-5KzZs2ljUIJuTQsaoWtWjaCeTQAON04LphnerGbmxlRYeBirpt667pMq0aqow2nDb8onh30F3SMMOos0OvTL94nJXf9U5h_z9icdOv3bZnjHLZMJkVXh8VvPueIMR-xrD3oCxk231bS1lVncjEywMxZxCCh-n0C6P9fhT6v6OQyS__7etEPWaf8VdHXAWtzORzSBhONCGrupMN_w0zBsJl</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75882294</pqid></control><display><type>article</type><title>In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells</title><source>MEDLINE</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>STOECK, M ; MARLAND-NOSKE, C ; MANASTERSKI, M ; ZAWATZKY, R ; HORN, S ; MÖBUS, V ; SCHLAG, P ; SCHIRRMACHER, V</creator><creatorcontrib>STOECK, M ; MARLAND-NOSKE, C ; MANASTERSKI, M ; ZAWATZKY, R ; HORN, S ; MÖBUS, V ; SCHLAG, P ; SCHIRRMACHER, V</creatorcontrib><description>In order to understand further the effects of Newcastle-disease-virus(NDV)-modified tumour vaccines we investigated the feasibility of isolating lymphocytes from the site of injection of patients undergoing postoperative active specific immunization (ASI) with autologous NDV-modified tumour cells. Delayed-type-hypersensitivity(DTH)-like reactions from five cancer patients were surgically removed, minced and the tissue particles were digested with collagenase and DNase. Lymphoid cells recovered were expanded in a highly efficient limiting-dilution analysis system optimized for T cell growth [Moretta et al. (1983) J Exp Med 157: 743] and lymphocyte microcultures (clonal probability &gt; 0.8) could be grown for up to 1 year. Analysis of the microcultures for phenotype and function showed that the majority were positive for CD4 (92%) and TCR alpha beta (96%). Concanavalin-A-induced production of interleukin-2 (IL-2), IL-6, interferon gamma and tumour necrosis factor alpha was detected in more than 70% of the microcultures. Lectin-dependent cytotoxicity was only very rarely observed. The general characteristics of the microcultures obtained support the notion of a DTH-like reaction taking place at the site of tumour cell challenge. The possibility of in vitro expansion and cultivation of T lymphocytes from ASI vaccination sites should help to elucidate further the role of these cells in active specific immunization against autologous tumour cells.</description><identifier>ISSN: 0340-7004</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/BF01518517</identifier><identifier>PMID: 8348563</identifier><identifier>CODEN: CIIMDN</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Antineoplastic agents ; Biological and medical sciences ; Cells, Cultured ; Cytokines - biosynthesis ; Cytotoxicity, Immunologic ; Humans ; Hypersensitivity, Delayed - immunology ; Immunophenotyping ; Immunotherapy ; Medical sciences ; Neoplasms - immunology ; Newcastle disease virus ; Original ; Pharmacology. Drug treatments ; T-Lymphocytes - immunology ; Vaccination - methods</subject><ispartof>Cancer Immunology Immunotherapy, 1993-09, Vol.37 (4), p.240-244</ispartof><rights>1993 INIST-CNRS</rights><rights>Springer-Verlag 1993</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c367t-5e4148b912545467fe8b6e130b3c619a9d9d7820bb0457759695462b2c6163063</citedby><cites>FETCH-LOGICAL-c367t-5e4148b912545467fe8b6e130b3c619a9d9d7820bb0457759695462b2c6163063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11038618/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11038618/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=4825986$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8348563$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>STOECK, M</creatorcontrib><creatorcontrib>MARLAND-NOSKE, C</creatorcontrib><creatorcontrib>MANASTERSKI, M</creatorcontrib><creatorcontrib>ZAWATZKY, R</creatorcontrib><creatorcontrib>HORN, S</creatorcontrib><creatorcontrib>MÖBUS, V</creatorcontrib><creatorcontrib>SCHLAG, P</creatorcontrib><creatorcontrib>SCHIRRMACHER, V</creatorcontrib><title>In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells</title><title>Cancer Immunology Immunotherapy</title><addtitle>Cancer Immunol Immunother</addtitle><description>In order to understand further the effects of Newcastle-disease-virus(NDV)-modified tumour vaccines we investigated the feasibility of isolating lymphocytes from the site of injection of patients undergoing postoperative active specific immunization (ASI) with autologous NDV-modified tumour cells. Delayed-type-hypersensitivity(DTH)-like reactions from five cancer patients were surgically removed, minced and the tissue particles were digested with collagenase and DNase. Lymphoid cells recovered were expanded in a highly efficient limiting-dilution analysis system optimized for T cell growth [Moretta et al. (1983) J Exp Med 157: 743] and lymphocyte microcultures (clonal probability &gt; 0.8) could be grown for up to 1 year. Analysis of the microcultures for phenotype and function showed that the majority were positive for CD4 (92%) and TCR alpha beta (96%). Concanavalin-A-induced production of interleukin-2 (IL-2), IL-6, interferon gamma and tumour necrosis factor alpha was detected in more than 70% of the microcultures. Lectin-dependent cytotoxicity was only very rarely observed. The general characteristics of the microcultures obtained support the notion of a DTH-like reaction taking place at the site of tumour cell challenge. The possibility of in vitro expansion and cultivation of T lymphocytes from ASI vaccination sites should help to elucidate further the role of these cells in active specific immunization against autologous tumour cells.</description><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Cells, Cultured</subject><subject>Cytokines - biosynthesis</subject><subject>Cytotoxicity, Immunologic</subject><subject>Humans</subject><subject>Hypersensitivity, Delayed - immunology</subject><subject>Immunophenotyping</subject><subject>Immunotherapy</subject><subject>Medical sciences</subject><subject>Neoplasms - immunology</subject><subject>Newcastle disease virus</subject><subject>Original</subject><subject>Pharmacology. Drug treatments</subject><subject>T-Lymphocytes - immunology</subject><subject>Vaccination - methods</subject><issn>0340-7004</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUk1v1DAUjBCobAsX7kg-IA6VAnbsJM4JlYpCpQou5Rw5zsvuQ44d_LFl-an8GrzsaoGD5Y-ZN36jeUXxgtE3jNL27fsbymoma9Y-KlZM8Kqk-fK4WFEuaNlSKp4W5yF8y4eKdt1ZcSa5kHXDV8WvW0u2GL0j8GNRNqCzRNkxL2V2AQNxE7knZjcvG6d3EciM2judTEweMjpEhRZGMnk3k7gBslVao1VxLxQwwh8FrawGT5b8DDYGkuwIfu3QronSEbdAwgIaJ9QE5zlZ_HkQeMC4ISpFZ9zapUA-w4NWIRooRwygApRb9CmUsxtzcW4jptklTzQYE54VTyZlAjw_7hfF15sP99efyrsvH2-vr-5KzZs2ljUIJuTQsaoWtWjaCeTQAON04LphnerGbmxlRYeBirpt667pMq0aqow2nDb8onh30F3SMMOos0OvTL94nJXf9U5h_z9icdOv3bZnjHLZMJkVXh8VvPueIMR-xrD3oCxk231bS1lVncjEywMxZxCCh-n0C6P9fhT6v6OQyS__7etEPWaf8VdHXAWtzORzSBhONCGrupMN_w0zBsJl</recordid><startdate>19930901</startdate><enddate>19930901</enddate><creator>STOECK, M</creator><creator>MARLAND-NOSKE, C</creator><creator>MANASTERSKI, M</creator><creator>ZAWATZKY, R</creator><creator>HORN, S</creator><creator>MÖBUS, V</creator><creator>SCHLAG, P</creator><creator>SCHIRRMACHER, V</creator><general>Springer</general><general>Springer-Verlag</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19930901</creationdate><title>In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells</title><author>STOECK, M ; MARLAND-NOSKE, C ; MANASTERSKI, M ; ZAWATZKY, R ; HORN, S ; MÖBUS, V ; SCHLAG, P ; SCHIRRMACHER, V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c367t-5e4148b912545467fe8b6e130b3c619a9d9d7820bb0457759695462b2c6163063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Cells, Cultured</topic><topic>Cytokines - biosynthesis</topic><topic>Cytotoxicity, Immunologic</topic><topic>Humans</topic><topic>Hypersensitivity, Delayed - immunology</topic><topic>Immunophenotyping</topic><topic>Immunotherapy</topic><topic>Medical sciences</topic><topic>Neoplasms - immunology</topic><topic>Newcastle disease virus</topic><topic>Original</topic><topic>Pharmacology. Drug treatments</topic><topic>T-Lymphocytes - immunology</topic><topic>Vaccination - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>STOECK, M</creatorcontrib><creatorcontrib>MARLAND-NOSKE, C</creatorcontrib><creatorcontrib>MANASTERSKI, M</creatorcontrib><creatorcontrib>ZAWATZKY, R</creatorcontrib><creatorcontrib>HORN, S</creatorcontrib><creatorcontrib>MÖBUS, V</creatorcontrib><creatorcontrib>SCHLAG, P</creatorcontrib><creatorcontrib>SCHIRRMACHER, V</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer Immunology Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>STOECK, M</au><au>MARLAND-NOSKE, C</au><au>MANASTERSKI, M</au><au>ZAWATZKY, R</au><au>HORN, S</au><au>MÖBUS, V</au><au>SCHLAG, P</au><au>SCHIRRMACHER, V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells</atitle><jtitle>Cancer Immunology Immunotherapy</jtitle><addtitle>Cancer Immunol Immunother</addtitle><date>1993-09-01</date><risdate>1993</risdate><volume>37</volume><issue>4</issue><spage>240</spage><epage>244</epage><pages>240-244</pages><issn>0340-7004</issn><eissn>1432-0851</eissn><coden>CIIMDN</coden><abstract>In order to understand further the effects of Newcastle-disease-virus(NDV)-modified tumour vaccines we investigated the feasibility of isolating lymphocytes from the site of injection of patients undergoing postoperative active specific immunization (ASI) with autologous NDV-modified tumour cells. Delayed-type-hypersensitivity(DTH)-like reactions from five cancer patients were surgically removed, minced and the tissue particles were digested with collagenase and DNase. Lymphoid cells recovered were expanded in a highly efficient limiting-dilution analysis system optimized for T cell growth [Moretta et al. (1983) J Exp Med 157: 743] and lymphocyte microcultures (clonal probability &gt; 0.8) could be grown for up to 1 year. Analysis of the microcultures for phenotype and function showed that the majority were positive for CD4 (92%) and TCR alpha beta (96%). Concanavalin-A-induced production of interleukin-2 (IL-2), IL-6, interferon gamma and tumour necrosis factor alpha was detected in more than 70% of the microcultures. Lectin-dependent cytotoxicity was only very rarely observed. The general characteristics of the microcultures obtained support the notion of a DTH-like reaction taking place at the site of tumour cell challenge. The possibility of in vitro expansion and cultivation of T lymphocytes from ASI vaccination sites should help to elucidate further the role of these cells in active specific immunization against autologous tumour cells.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>8348563</pmid><doi>10.1007/BF01518517</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0340-7004
ispartof Cancer Immunology Immunotherapy, 1993-09, Vol.37 (4), p.240-244
issn 0340-7004
1432-0851
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11038618
source MEDLINE; PubMed Central; SpringerLink Journals - AutoHoldings
subjects Antineoplastic agents
Biological and medical sciences
Cells, Cultured
Cytokines - biosynthesis
Cytotoxicity, Immunologic
Humans
Hypersensitivity, Delayed - immunology
Immunophenotyping
Immunotherapy
Medical sciences
Neoplasms - immunology
Newcastle disease virus
Original
Pharmacology. Drug treatments
T-Lymphocytes - immunology
Vaccination - methods
title In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T16%3A05%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20expansion%20and%20analysis%20of%20T%20lymphocyte%20microcultures%20obtained%20from%20the%20vaccination%20sites%20of%20cancer%20patients%20undergoing%20active%20specific%20immunization%20with%20autologous%20Newcastle-disease-virus-modified%20tumour%20cells&rft.jtitle=Cancer%20Immunology%20Immunotherapy&rft.au=STOECK,%20M&rft.date=1993-09-01&rft.volume=37&rft.issue=4&rft.spage=240&rft.epage=244&rft.pages=240-244&rft.issn=0340-7004&rft.eissn=1432-0851&rft.coden=CIIMDN&rft_id=info:doi/10.1007/BF01518517&rft_dat=%3Cproquest_pubme%3E75882294%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75882294&rft_id=info:pmid/8348563&rfr_iscdi=true